Pain Clinic

NexCore Group and Montrose Regional Health Open New Ambulatory Care Center in Western Colorado

Retrieved on: 
Thursday, May 9, 2024
ACC, CPH, Ambulatory care, Spine, Pain Clinic, Trustmark (bank), Uncompahgre Valley, MRH, Patient, Physician, SF

DENVER, May 9, 2024 /PRNewswire-PRWeb/ -- NexCore Group, a leading healthcare real estate development, investment, and management company, and Montrose Regional Health ("MRH"), celebrated the opening of a new Ambulatory Care Center ("ACC") in Montrose, Colorado on April 25, 2024.

Key Points: 
  • DENVER, May 9, 2024 /PRNewswire-PRWeb/ -- NexCore Group , a leading healthcare real estate development, investment, and management company, and Montrose Regional Health ("MRH"), celebrated the opening of a new Ambulatory Care Center ("ACC") in Montrose, Colorado on April 25, 2024.
  • "NexCore Group is thrilled to have partnered with Montrose Regional Health on this new Ambulatory Care Center.
  • The 3rd floor is exclusively leased to Cedar Point Health ("CPH"), the largest primary care provider group in the region.
  • "NexCore Group is thrilled to have partnered with Montrose Regional Health on this new Ambulatory Care Center.

Israeli Ministry of Health Reports Surge in Medical Cannabis Patients Following Recent Events

Retrieved on: 
Tuesday, November 7, 2023
Cannabis, FDA, Spectrum, Intelligence, Psychiatry, Ageing, Ministry of Health (Israel), Family, Physician, Data collection, BYND, Pain Clinic, CSE, Ministry, BCAN, CRM, Epilepsy, Patient, Software as a service, Nursing, Pharmaceutical industry

Recent regulatory reforms approved by the Israeli Ministry of Healthi allows physicians to prescribe cannabis to patients as a first-line treatment rather than as an option of last resort.

Key Points: 
  • Recent regulatory reforms approved by the Israeli Ministry of Healthi allows physicians to prescribe cannabis to patients as a first-line treatment rather than as an option of last resort.
  • Israel has had a significant increase in the number of licensed medical cannabis patientsii in the wake of recent events, particularly the opening of the war in Gaza.
  • Physicians licensed to prescribe medical cannabis and Israeli Ministry of Health authorities have reported a notable surge in demand after the recent conflict.
  • Many of the medical cannabis patients receiving new licenses are war casualties, as doctors began issuing licenses for post-trauma to victims of the recent events.

Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom

Retrieved on: 
Thursday, July 20, 2023
Science, Biotechnology, Research, Physical Therapy, Health, Medical Devices, Fitness & Nutrition, Clinical Trials, Chronic pain, Pain Clinic, Patient, Safety, Nursing, Pain

Dr. Simon Thomson MBBS FFPMRCA, Consultant Lead at the Pain and Neuromodulation Centre, Mid and South Essex University Hospitals NHS, Essex, UK, stated: “These results demonstrate durability and safety of this therapy in chronic back pain sufferers who would have continued to be crippled and dominated by their symptoms but for ReActiv8.

Key Points: 
  • Dr. Simon Thomson MBBS FFPMRCA, Consultant Lead at the Pain and Neuromodulation Centre, Mid and South Essex University Hospitals NHS, Essex, UK, stated: “These results demonstrate durability and safety of this therapy in chronic back pain sufferers who would have continued to be crippled and dominated by their symptoms but for ReActiv8.
  • These patients, drawn from usual UK Pain clinics, are now as good as those seen in the continuation cohort from the more highly selected randomised ReActiv8-B trial.”
    Jason Hannon, CEO of Mainstay Medical, stated: “We are pleased to add these compelling results to the growing global body of positive peer-reviewed evidence supporting the ability of ReActiv8 to provide positive long-term outcomes to this severely affected patient population.
  • Most importantly, the continued improvement in patient outcomes observed in the real-world setting is consistent with the results from our controlled clinical trials.”

Dr. Andres Betts Joins Pain Medicine Associates - Mission Viejo, California

Retrieved on: 
Tuesday, July 18, 2023
Pain disorder, University, Long Beach, California, Cranial nerves, Critical Care Medicine (journal), Skiing, Sciatica, Alfred Noble Prize, Spine, Radiofrequency ablation, Suite, Piriformis syndrome, PMA, University of California, Irvine Medical Center, Patient, Physician, Pain Clinic, Associate, Mountaineering, Pain, Diagnosis, Sacral fracture, Bone fracture, General surgery, Nursing, Dentistry, Anesthesiology, Medicine

MISSION VIEJO, Calif., July 18, 2023 /PRNewswire-PRWeb/ -- Pain Medicine Associates (PMA) is pleased to announce that interventional pain management specialist Andres Betts, M.D., has joined the company's Mission Viejo, California pain management practice. He began seeing patients on July 3rd at the office, located at 26137 La Paz Rd, Suite 140, Mission Viejo, CA 92691.

Key Points: 
  • MISSION VIEJO, Calif., July 18, 2023 /PRNewswire-PRWeb/ -- Pain Medicine Associates (PMA) is pleased to announce that interventional pain management specialist Andres Betts, M.D., has joined the company's Mission Viejo, California pain management practice.
  • He began seeing patients on July 3rd at the office, located at 26137 La Paz Rd, Suite 140, Mission Viejo, CA 92691.
  • Dr. Betts is an innovative, board-certified, fellowship trained interventional pain management physician that specializes in the diagnosis and treatment of pain disorders.
  • He founded the Pain Clinic in Bellingham, Washington and Pain MD Medical Associates in San Clemente, California.

Dr. Peter Staats, Chief Medical Officer at National Spine and Pain, Joins the Neuralace Medical Advisory Board as the Company Continues its Successful Seed Round Fundraising, Building Off the First Close of $3.1M While Targeting a Total Capital Raise of $

Retrieved on: 
Thursday, May 25, 2023
Augusta University, Medical college, Department of Defence, Medical College of Georgia, DRS, Axon, Veterans Health Administration, Veteran, Associate, PNS, Charlie Norwood, Pain, Addiction medicine, Society of Chest Pain Centers, Patient, Pain Clinic, Pain management, FDA, Dentistry, Medical device, Bedder

SAN DIEGO, May 25, 2023 /PRNewswire/ -- Neuralace Medical, Inc., a leading medical technology company specializing in innovative non-invasive solutions for the treatment of chronic peripheral neuropathic pain, is pleased to welcome Dr. Peter Staats, Chief Medical Officer at National Spine and Pain Centers, based in Frederick, MD., to the Neuralace Medical Advisory Board. Dr. Staats brings extensive expertise to the company and will collaborate with the advisory board and Neuralace Medical to contribute valuable insights and strategic guidance. He expressed his enthusiasm for Axon Therapy, stating, "I have seen Axon Therapy progress from an interesting project several years ago, to what is now an FDA cleared, clinically impactful treatment. Axon Therapy is an excellent complement to conventional, implantable neuromodulation, bringing the benefits of neurostimulation to many more patients. I look forward to working alongside Drs. Sayed (KU Medical Center), Kapural (Carolina Pain Institute), and Bedder (VAMC Augusta) to support the market entry of this much-needed non-invasive approach."

Key Points: 
  • Dr. Staats brings extensive expertise to the company and will collaborate with the advisory board and Neuralace Medical to contribute valuable insights and strategic guidance.
  • Axon Therapy is an excellent complement to conventional, implantable neuromodulation, bringing the benefits of neurostimulation to many more patients.
  • Sayed (KU Medical Center), Kapural (Carolina Pain Institute), and Bedder (VAMC Augusta) to support the market entry of this much-needed non-invasive approach."
  • This milestone establishes Charlie Norwood VA Medical Center as the first VA Medical Center to incorporate Axon Therapy into its treatment regimen.

Healint announces a collaboration with University of Toronto, Canada, to study the role of pollution on Migraine

Retrieved on: 
Wednesday, February 1, 2023
Air pollution, Environment, Smartphone, Emergency, Canada, Climate change, Weather, Patient, Work, Dalla Lana School of Public Health, Environment and Climate Change Canada, Oxidative stress, Migraine, Clutch (eggs), Research, PALO, University, Risk, Disease, Public health, DSM-IV codes, Pain Clinic, Public, Doctor of Philosophy, Pharmaceutical industry

Healint's objective is to help research and promote a better understanding of migraine to improve disease management.

Key Points: 
  • Healint's objective is to help research and promote a better understanding of migraine to improve disease management.
  • The objective of the study will be to determine the association between air pollution and risk of migraine attack onset using administrative and smartphone data.
  • Given that exposure to air pollution is ubiquitous, an association of migraine with air pollution would have important worldwide implications for public health and environmental monitoring and intervention.
  • "This collaboration with Healint is a great opportunity for us to access data otherwise unavailable and address current gaps in the understanding of migraine triggers," said Ms. Portt.

ManagingLife Attains SOC2 Type 2 Certification

Retrieved on: 
Thursday, September 22, 2022
AICPA, Disability, Time, Confidentiality, Trust, American Institute, Corporation, Privacy, Organization, Compliance, CPAS, Patient, Type 2, Certification, SOC, Pain, Solution, Security, Pain management, Pain Clinic, Type 1, Chronic pain, Self-management, Audit, Criterion

TORONTO, Sept. 22, 2022 /PRNewswire/ --  ManagingLife, an industry-leading digital health provider of pain management solutions, today announced that it has successfully achieved SOC2 Type 2 certification for its Manage My Pain solution. The certification, conducted by Johanson Group LLP, found zero exceptions across all 5 Trust Services Criteria.

Key Points: 
  • TORONTO, Sept. 22, 2022 /PRNewswire/ -- ManagingLife , an industry-leading digital health provider of pain management solutions,today announced that it has successfully achieved SOC2 Type 2 certification for its Manage My Pain solution.
  • ManagingLife recently achieved Type 1 compliance which verified the existence of internal controls outlined in the Trust Services Principles and Criteria for Security.
  • For its Type 2 certification, ManagingLife expanded the scope of its SOC2 compliance to all 5 Trust Services Criteria and demonstrated that the appropriate controls were implemented over a period of time.
  • "Successfully achieving SOC 2 Type 2 certification with zero exceptions across all Trust Criteria demonstrates ManagingLife's commitment to protecting the information of our users," said Tahir Jamohamed, ManagingLife Chief Executive Officer.

ManagingLife Expands Self-Management in its Digital Chronic Pain Solution

Retrieved on: 
Tuesday, September 20, 2022
Disability, Corporation, University Health Network, Google, Patient, Mental health, Apple, Chronic pain, Pain, Quality of life, Comorbidity, Mixed anxiety–depressive disorder, Pain management, Pain Clinic, Medical director, Self-management, Poultry, Dentistry

TORONTO, Sept. 20, 2022 /PRNewswire/ -- ManagingLife, the developer of the digital pain management solution, Manage My Pain, is excited to announce the introduction of the Pain Guide as part of its solution. The Pain Guide was created by specialists and inspired by best practices in pain psychology to provide users with educational content about pain and ways to manage it.

Key Points: 
  • TORONTO, Sept. 20, 2022 /PRNewswire/ -- ManagingLife, the developer of the digital pain management solution , Manage My Pain, is excited to announce the introduction of the Pain Guide as part of its solution.
  • Despite the comorbidity of mental health and chronic pain, the vast majority of people with chronic pain never receive psychological support.
  • Developed by a multidisciplinary team of pain experts, the Pain Guide introduces topics that are typically discussed by pain psychologists such as how pain works and strategies to cope.
  • The Pain Guide will be offered to all subscribers of Manage My Pain, including those who receive access to the solution from their pain clinics or insurer.

Milestone Scientific Announces Distribution Agreement with Clinical Technology, Inc. for the CompuFlo® Epidural System

Retrieved on: 
Thursday, August 4, 2022
FDA, U.S. Securities and Exchange Commission, Pain management, Risk, Indian Medical Association, Injection, American Medical Association, NYSE, GLOBE, Failure, Technology, Hospital, Security (finance), Annual report, LOR, MLSS, Partnership, Safety, Disease, Pain Clinic, Category, Physician, AMA, Anesthesiology, CTI, Adoption, Medical device, Pharmaceutical industry, Milestone

Kent Krafft, Vice President of Clinical Technology Inc., stated, When we were initially introduced to Milestones CompuFlo Epidural System in 2018, we immediately recognized the tremendous clinical and safety benefits.

Key Points: 
  • Kent Krafft, Vice President of Clinical Technology Inc., stated, When we were initially introduced to Milestones CompuFlo Epidural System in 2018, we immediately recognized the tremendous clinical and safety benefits.
  • Our collaboration with Milestone Scientific to advance the commercial rollout of the CompuFlo Epidural System is a critical step towards providing a modern and safer solution to pain management for both hospitals, and now, private pain clinics.
  • Milestone Scientifics computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety.
  • Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Outlook on the Opioids Global Market to 2027 - High Incidence of Chronic Pain in Adults and Demand for Strong Agonists are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022
Health, Pharmaceutical, Time, CAGR, Palliative care, Cough, Public health, Infection, COVID-19, United States drug overdose death rates and totals over time, Fentanyl, Safety, Death, Hydrocodone, Pethidine, Codeine, Morphine, Drug, Knowledge, Efficiency, National Vital Statistics System, OMT, Research, Pain, Hospital, Methadone, National, Chronic pain, Analgesic, Diarrhea, Oxycodone, Oxymorphone, Drug overdose, Incidence, Patient, Application, Awareness, CDC, Prevalence, Pain Clinic, Cereal, Poultry, Pharmaceutical industry

The Global Opioids Market size is expected to reach $5.4 billion by 2027, rising at a market growth of 3.5% CAGR during the forecast period.

Key Points: 
  • The Global Opioids Market size is expected to reach $5.4 billion by 2027, rising at a market growth of 3.5% CAGR during the forecast period.
  • Opioids essentially serve as pain relievers since they are composed of substances that relax muscles and alleviate pain and stress.
  • Opioids are the most commonly prescribed pain relievers for people suffering from moderate to severe chronic pain.
  • Individuals diagnosed with terminal illnesses suffering from severe and chronic physical pain are the main recipient of these analgesics.